Osteogenesis Imperfecta Treatment Market
According to Intent Market Research, the Osteogenesis Imperfecta Treatment Market is expected to grow from USD 1.1 Billion in 2024-e at a CAGR of 22.7% to touch USD 3.8 Billion by 2030. The Osteogenesis Imperfecta Treatment Market is dominated by key players such as Novartis AG, Amgen Inc., Merial Inc., Baxter International Inc., Ultragenyx Pharmaceutical Inc., and Ipsen S.A..